18 F FDG PET-CT as an Early Prognosticator of Response to Treatment: Monitoring Hormone Receptor-Positive Breast Cancer Under CDK4/6 Inhibitor Treatment with Serial Imaging (EANM 2026) - Sep 29, 2026 - Abstract #EP-0297; "Materials and This retrospective study included patients with metastatic PR+/ER+ breast cancer treated with CDK4/6 inhibitors (Palbociclib, Abemaciclib, or Ribociclib) who underwent baseline 18F FDG PET-CT and subsequent surveillance at 3-monthly intervals. Early metabolic response (Δ MTV) is the dominant driver of PFS, outperforming baseline MTV and clinical variables. Serial 18F FDG PET-CT surveillance allows for robust risk stratification; specifically, patients with a >90% reduction in MTV at 3 months may transition to less frequent surveillance, potentially reducing the total number of required PET scans by nearly half. Conversely, failure to achieve a complete metabolic response (defined as MTV=0 even in the presence of visually assessable residual disease) by the third PET scan indicates a high risk of treatment failure."
FDG PET • Breast Cancer • Estrogen Receptor Positive Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
|
|
F. Alorfi; Z. Haq; D. Priftakis; S. Voo; K. De Souza; Y. Mathur
|